Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: a series of 20 patients

Dereure, O.; Raison‐Peyron, Nadia; Larrey, Dominique; Blanc, F; Jj, Guilhou

doi:10.1046/j.1365-2133.2002.04897.x

Cited by 73 publications

(47 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Topical corticosteroids and anti-H 1 antihistaminic drugs were sufficient to alleviate the symptoms in most patients, allowing the treatment to be continued. Inflammatory eczema-like reactions at a distance of injection sites induced by interferon therapy have already been observed in patients with hepatitis C virus infection treated with low-dose interferon and ribavirin [14]. In these cases however, the eruption appears to be severer and is often localized or predominant in distal and/or photoexposed areas.…”

Section: Discussionmentioning

confidence: 99%

A Prospective Study of Cutaneous Adverse Events Induced by Low-Dose Alpha-Interferon Treatment for Malignant Melanoma

et al. 2004

Self Cite

View full text Add to dashboard Cite

Introduction: α-Interferon is associated with numerous cutaneous side effects, but the accurate incidence of these complications is not clearly known. Objectives: A prospective study was designed to evaluate the incidence and clinical pattern of cutaneous side effects in a cohort of patients receiving adjuvant therapy with low-dose interferon for malignant melanoma. Material and Methods: A cohort of 33 patients with stage IIA and IIB melanoma treated with low-dose α-interferon (3 MIU 3 times a week for 18 months) were prospectively enrolled in a single-center study. The patients responded to a questionnaire on their medical history and were systematically examined for any cutaneous lesions before treatment and every 3 months afterwards. Results: 29/33 patients (87%) experienced 1 or more cutaneous side effects. The most frequent was hair loss and occurred in 16 cases (48.4%). Hair discoloration was noted in 6 cases (18%). Eczematous reactions at injection sites or at remote sites were observed in 13 patients (39%). Pruritus occurred in 10 cases (30%). Xerostomia, Raynaud’s phenomenon or livedo reticularis were observed in 10 patients, associated with an increase in circulating autoantibody titer in 2 cases. Some rare side effects were observed: urticaria (1 case) or angioedema (1 case), worsening of preexisting seborrheic dermatitis (3 cases), herpetic recurrence (2 cases), pityriasis versicolor (1 case), worsening of recurrent buccal aphthous ulcer (1 case) and vitiligo (1 case). Conclusion: Cutaneous adverse events during adjuvant immunotherapy of melanoma with low-dose α-interferon seem to be frequent but do not result in treatment discontinuation. A good awareness of these side effects may be useful for a more accurate survey and clinical management of patients receiving this treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

A Prospective Study of Cutaneous Adverse Events Induced by Low-Dose Alpha-Interferon Treatment for Malignant Melanoma

et al. 2004

Self Cite

View full text Add to dashboard Cite

show abstract

“…This drug may also induce a large number of cutaneous reactions. These are psoriasis, eczema or lichenoid eruptions, skin dryness, granulomatous infiltrates, photosensitivity and acrosyndromes [24,[25][26][27][28].…”

Section: Treatment-related Cutaneous Manifestationsmentioning

confidence: 99%

Myeloproliferative disorder therapy: assessment and management of adverse events—a dermatologist's perspective

Soutou

Aractingi

2009

Hematological Oncology

View full text Add to dashboard Cite

Development of cutaneous manifestations in patients with myeloproliferative disorders can be either due to the course of the disease itself or induced by some of the treatments given. The cutaneous manifestations may reveal an unknown haemopathy and/or indicate a poor prognosis. Some of these alter quality of life. Hydroxyurea has been shown to induce a variety of cutaneous adverse reactions ranging from benign effects such as hyperpigmentation to more severe leg ulcers and squamous cell carcinomas. Herein, we discuss the importance of undertaking regular physical examinations in order to identify and treat cutaneous manifestations early in their course.

show abstract

“…This reason gives rise to thought that skin eruptions might be seen more frequent due to ribavirin. In some of the studies, skin lesions were resolved without discontinuation of therapy in the majority of patients (9,10,11). In one of these studies performed by Patrk and colleagues, it is pointed that the number of patients followed without discontinuation of therapy was less than the number of those continued therapy (9).…”

Section: Discussionmentioning

confidence: 99%

Chronic Hepatitis C Treatment-Related Skin Rash: A Report of Two Cases

Gülen¹,

İmre²

2015

vhd

View full text Add to dashboard Cite

Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: a series of 20 patients

Cited by 73 publications

References 23 publications

A Prospective Study of Cutaneous Adverse Events Induced by Low-Dose Alpha-Interferon Treatment for Malignant Melanoma

A Prospective Study of Cutaneous Adverse Events Induced by Low-Dose Alpha-Interferon Treatment for Malignant Melanoma

Myeloproliferative disorder therapy: assessment and management of adverse events—a dermatologist's perspective

Chronic Hepatitis C Treatment-Related Skin Rash: A Report of Two Cases

Contact Info

Product

Resources

About